Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Official Title

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Brief Summary

      The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes
      of corneal blindness. Some categories of patients, including those with auto-immune diseases
      such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane
      pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the
      cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro
      and loss of the eye.

      Infliximab is an antibody against tumor necrosis factor alpha and is used intravenously to
      control inflammation in several diseases. It has been used in some cases of corneal melting
      with significant success.

      This study's hypothesis is that infliximab can be successfully used as an eye drop (instead
      of the usual administration through veins) and that its regular use may prevent melt in eyes
      with a Boston Keratoprosthesis type I and underlying auto-immune disease.

Detailed Description

      This is an unmasked, prospective, multicenter clinical trial of four patients that are
      candidates for a Boston Keratoprosthesis or have had prior KPro surgery and have a diagnosis
      of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis syndrome (TENS) or mucous
      membrane pemphigoid (MMP). Only one eye per patient will be considered for inclusion.

      This is a phase I/II study to evaluate the safety and tolerance of topical infliximab 10
      mg/mL eye drops. Research subjects will be required to administer infliximab eye drops four
      times per day for three months followed by twice daily administration for nine months. The
      subjects will be monitored while on the study medication as well as for one year following
      discontinuation of the drug. The total study duration for each patient will be two years.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome


Secondary Outcome

 Visual acuity


Stevens-Johnson Syndrome


topical infliximab

Study Arms / Comparison Groups

 topical infliximab
Description:  topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2014

Completion Date

April 3, 2017

Primary Completion Date

April 3, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Age between 18 and 80 years

          -  Able to provide informed consent

          -  Underlying diagnosis of SJS, TENS, or MMP

          -  Implantation of a Boston KPro type I

          -  Able to administer eye medications or have a care giver able and willing to do same

          -  Negative tuberculosis screening

        Exclusion Criteria:

          -  Active or recurrent ocular or systemic infection

               -  Chest radiography, QuantiFERON-TB Gold or purified protein derivative (PPD)
                  evidence of active or latent tuberculosis infection

               -  Indeterminate initial and repeat QuantiFERON-TB Gold results

               -  History of Bacille Calmette-Guerin (BCG) vaccination within twelve months of

               -  History of latent or active granulomatous infection, including histoplasmosis or
                  coccidioidomycosis, prior to screening

               -  Chest radiograph within three months prior to the first administration of the
                  study drug that shows an abnormality suggestive of a malignancy or current active
                  infection, including tuberculosis.

               -  History of a nontuberculous mycobacterial infection or opportunistic infection
                  (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within six months prior to

               -  history of hepatitis B virus

               -  Methicillin resistant Staphylococcus aureus (MRSA) or vancomycin resistant
                  enterococcus (VRE) infection

          -  Malignancy diagnosed in the last five years

          -  Demyelinating disease

          -  History or current diagnosis of diabetes mellitus (controlled and uncontrolled)

          -  Heart failure (New York Heart Association class III or IV)

          -  Pregnancy or breast-feeding

          -  Scheduled to receive a live vaccine at any time point during study participation

          -  Allergy to infliximab or any of the compounds in its topical formulation or any
             chemically-related medication

          -  Prior or current use of systemic anti-tumor necrosis alpha-α medications or currently
             receiving treatments of Kineret (Anakinra)

          -  KPro designs with less than 16 holes in the back plate (to avoid the confounder of
             corneal nutrition)

          -  Inability to comply with the instillation of additional drops

          -  Unable to attend postoperative visits or administer medications, or no care giver
             available and willing to assist with same




18 Years - 80 Years

Accepts Healthy Volunteers



James Chodosh, MD, MPH, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

MEEI 13-110H

Secondary IDs

IND 122719

Responsible Party


Study Sponsor

James Chodosh, MD, MPH


 Massachusetts Eye and Ear Infirmary

Study Sponsor

James Chodosh, MD, MPH, Principal Investigator, Massachusetts Eye and Ear Infirmary

Verification Date

April 2017